These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 26250749)
21. Diet1 is a regulator of fibroblast growth factor 15/19-dependent bile acid synthesis. Reue K; Lee JM; Vergnes L Dig Dis; 2015; 33(3):307-13. PubMed ID: 26045262 [TBL] [Abstract][Full Text] [Related]
22. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Uriarte I; Fernandez-Barrena MG; Monte MJ; Latasa MU; Chang HC; Carotti S; Vespasiani-Gentilucci U; Morini S; Vicente E; Concepcion AR; Medina JF; Marin JJ; Berasain C; Prieto J; Avila MA Gut; 2013 Jun; 62(6):899-910. PubMed ID: 23292666 [TBL] [Abstract][Full Text] [Related]
23. The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. Wang LX; Frey MR; Kohli R Front Endocrinol (Lausanne); 2021; 12():799648. PubMed ID: 35116006 [TBL] [Abstract][Full Text] [Related]
24. Intestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice. Bozadjieva-Kramer N; Shin JH; Shao Y; Gutierrez-Aguilar R; Li Z; Heppner KM; Chiang S; Vargo SG; Granger K; Sandoval DA; MacDougald OA; Seeley RJ Nat Commun; 2021 Aug; 12(1):4768. PubMed ID: 34362888 [TBL] [Abstract][Full Text] [Related]
25. Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Naugler WE; Tarlow BD; Fedorov LM; Taylor M; Pelz C; Li B; Darnell J; Grompe M Gastroenterology; 2015 Sep; 149(3):728-40.e15. PubMed ID: 26028580 [TBL] [Abstract][Full Text] [Related]
26. Attenuated Accumulation of Novel Fluorine ( Metry M; Felton J; Cheng K; Xu S; Ai Y; Xue F; Raufman JP; Polli JE Mol Pharm; 2018 Nov; 15(11):4827-4834. PubMed ID: 30247920 [TBL] [Abstract][Full Text] [Related]
27. Roles of FGF19 in liver metabolism. Kir S; Kliewer SA; Mangelsdorf DJ Cold Spring Harb Symp Quant Biol; 2011; 76():139-44. PubMed ID: 21813638 [TBL] [Abstract][Full Text] [Related]
29. Effects of intestine-specific deletion of FGF15 on the development of fatty liver disease with vertical sleeve gastrectomy. Chow MD; Otersen K; Wassef A; Kong B; Yamarthy S; Rizzolo D; Yang I; Buckley B; Lu A; Crook N; Lee M; Gao J; Naganand S; Stofan MF; Armstrong L; Schumacher J; Taylor R; Henry Z; Basaly V; Yang Z; Zhang M; Huang M; Kagan L; Brunetti L; Sadek R; Lee YH; Guo GL Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780301 [TBL] [Abstract][Full Text] [Related]
30. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Vergnes L; Lee JM; Chin RG; Auwerx J; Reue K Cell Metab; 2013 Jun; 17(6):916-928. PubMed ID: 23747249 [TBL] [Abstract][Full Text] [Related]
32. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976 [TBL] [Abstract][Full Text] [Related]
33. Role of fibroblast growth factor 19 in the control of glucose homeostasis. Schaap FG Curr Opin Clin Nutr Metab Care; 2012 Jul; 15(4):386-91. PubMed ID: 22617565 [TBL] [Abstract][Full Text] [Related]
34. Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. Rizzolo D; Kong B; Piekos S; Chen L; Zhong X; Lu J; Shi J; Zhu HJ; Yang Q; Li A; Li L; Wang H; Siemiątkowska A; Park C; Kagan L; Guo GL Drug Metab Dispos; 2022 Apr; 50(4):468-477. PubMed ID: 34965924 [TBL] [Abstract][Full Text] [Related]
35. Telling the liver (not) to make bile acids: a new voice from the gut? Angelin B Cell Metab; 2005 Oct; 2(4):209-10. PubMed ID: 16213221 [TBL] [Abstract][Full Text] [Related]
36. Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance. Bozadjieva-Kramer N; Shin JH; Li Z; Rupp AC; Miller N; Kernodle S; Lanthier N; Henry P; Seshadri N; Myronovych A; MacDougald OA; O'Rourke RW; Kohli R; Burant CF; Rothberg AE; Seeley RJ JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587078 [TBL] [Abstract][Full Text] [Related]
37. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587 [TBL] [Abstract][Full Text] [Related]
38. Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. Han S; Zhang R; Jain R; Shi H; Zhang L; Zhou G; Sangwung P; Tugal D; Atkins GB; Prosdocimo DA; Lu Y; Han X; Tso P; Liao X; Epstein JA; Jain MK Nat Commun; 2015 Jun; 6():7231. PubMed ID: 26040986 [TBL] [Abstract][Full Text] [Related]
39. Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets. Ferrell JM; Chiang JYL Diabetes Metab J; 2019 Jun; 43(3):257-272. PubMed ID: 31210034 [TBL] [Abstract][Full Text] [Related]
40. Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. Donate-Correa J; Martín-Núñez E; Delgado NP; de Fuentes MM; Arduan AO; Mora-Fernández C; Navarro González JF Cytokine Growth Factor Rev; 2016 Apr; 28():71-7. PubMed ID: 26706229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]